238 related articles for article (PubMed ID: 17659636)
1. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
Simonis G; Fuhrmann JT; Strasser RH
Mov Disord; 2007 Oct; 22(13):1936-42. PubMed ID: 17659636
[TBL] [Abstract][Full Text] [Related]
2. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
Kim JY; Chung EJ; Park SW; Lee WY
Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
[TBL] [Abstract][Full Text] [Related]
3. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
4. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
[TBL] [Abstract][Full Text] [Related]
5. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
Junghanns S; Fuhrmann JT; Simonis G; Oelwein C; Koch R; Strasser RH; Reichmann H; Storch A
Mov Disord; 2007 Jan; 22(2):234-8. PubMed ID: 17094087
[TBL] [Abstract][Full Text] [Related]
6. Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies.
Tran T; Brophy JM; Suissa S; Renoux C
CNS Drugs; 2015 Dec; 29(12):985-98. PubMed ID: 26585874
[TBL] [Abstract][Full Text] [Related]
7. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
[TBL] [Abstract][Full Text] [Related]
9. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
Horvath J; Fross RD; Kleiner-Fisman G; Lerch R; Stalder H; Liaudat S; Raskoff WJ; Flachsbart KD; Rakowski H; Pache JC; Burkhard PR; Lang AE
Mov Disord; 2004 Jun; 19(6):656-62. PubMed ID: 15197703
[TBL] [Abstract][Full Text] [Related]
10. Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease.
Rasmussen VG; Poulsen SH; Dupont E; Østergaard K; Safikhany G; Egeblad H
J Intern Med; 2008 Jan; 263(1):90-8. PubMed ID: 18036161
[TBL] [Abstract][Full Text] [Related]
11. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
[TBL] [Abstract][Full Text] [Related]
12. DA agonists -- ergot derivatives: pergolide: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S79-82. PubMed ID: 12211145
[No Abstract] [Full Text] [Related]
13. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
Pullan PT
Intern Med J; 2009 Apr; 39(4):213-5. PubMed ID: 19402858
[No Abstract] [Full Text] [Related]
14. Heart abnormalities in Parkinson patients after discontinuation or continuation of ergot-derived dopamine agonists: a treatment-blinded echocardiographic study.
Rasmussen VG; Poulsen SH; Dupont E; Østergaard K; Safikhany G; Egeblad H
J Heart Valve Dis; 2009 Jul; 18(4):463-9. PubMed ID: 19852154
[TBL] [Abstract][Full Text] [Related]
15. Dopamine agonists and the risk of cardiac-valve regurgitation.
Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
[TBL] [Abstract][Full Text] [Related]
16. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
Senol MG; Togrol RE
Neurology; 2007 Jul; 69(1):117; author reply 117-8. PubMed ID: 17606893
[No Abstract] [Full Text] [Related]
17. Pergolide in Parkinson's disease: time for a change?
Grosset KA; Grosset DG
Lancet; 2004 Jun; 363(9424):1907-8. PubMed ID: 15183636
[No Abstract] [Full Text] [Related]
18. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
Corvol JC; Anzouan-Kacou JB; Fauveau E; Bonnet AM; Lebrun-Vignes B; Girault C; Agid Y; Lechat P; Isnard R; Lacomblez L
Arch Neurol; 2007 Dec; 64(12):1721-6. PubMed ID: 18071034
[TBL] [Abstract][Full Text] [Related]
19. Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease.
Nakaoka S; Ishizaki T; Urushihara H; Satoh T; Ikeda S; Morikawa K; Nakayama T
Intern Med; 2011; 50(7):687-94. PubMed ID: 21467699
[TBL] [Abstract][Full Text] [Related]
20. Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
Trifirò G; Morgante L; Tari M; Arcoraci V; Savica R
J Am Geriatr Soc; 2008 Feb; 56(2):371-3. PubMed ID: 18251828
[No Abstract] [Full Text] [Related]
[Next] [New Search]
